Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The extended human
acetylcholinesterase
(
AChE
) promoter contains many binding sites for osteogenic factors, including 1,25-(OH)2 vitamin D3 and 17beta-estradiol. In differentiating
osteosarcoma
Saos-2 cells, both of these factors enhanced transcription of the
AChE
mRNA variant 3' terminated with exon 6 (E6-
AChE
mRNA), which encodes the catalytically and morphogenically active E6-
AChE
isoform. In contrast, antisense oligodeoxynucleotide suppression of E6-
AChE
mRNA expression increased Saos-2 proliferation in a dose- and sequence-dependent manner. The antisense mechanism of action was most likely mediated by mRNA destruction or translational arrest, as cytochemical staining revealed reduction in
AChE
gene expression. In vivo, we found that E6-
AChE
mRNA levels rose following midgestation in normally differentiating, postproliferative fetal chondrocytes but not in the osteogenically impaired chondrocytes of dwarf fetuses with thanatophoric dysplasia. Taken together, these findings suggest morphogenic involvement of E6-
AChE
in the proliferation-differentiation balance characteristic of human osteogenesis.
...
PMID:Human osteogenesis involves differentiation-dependent increases in the morphogenically active 3' alternative splicing variant of acetylcholinesterase. 985 1
The adhesive interactions that occur between bone cells and the developing matrix during bone formation help guide coupled remodeling and the maintenance of bone mass. Here, we provide evidence that
acetylcholinesterase
(
AChE
) is a novel osteoblast-derived mediator of cell-matrix interactions in bone. These findings complement an increasing body of evidence which suggests that
AChE
, in addition to its role in terminating cholinergic signaling, may be instrumental in regulating cellular differentiation and adhesion. We have shown, using RT-PCR, that
osteosarcoma
cell lines and primary cultures of osteoblasts express
AChE
mRNA. Expression appeared to be differentiation-dependent, and restricted to
AChE
splice variants containing the T subunit (exon 6). Immunofluorescent localization demonstrated that these osteoblastic cells expressed protein for
AChE
with an intracellular vesicular distribution. Immunohistochemistry on tissue sections confirmed
AChE
expression by osteoblasts in vivo, and revealed the presence of
AChE
along cement lines, also identified by enzyme histochemistry. In vitro functional studies indicated that osteoblast-like cells adhered specifically to and spread on
AChE
substrates, but did not interact with butyrylcholinesterase, a closely related protein. Our evidence strongly implicates
AChE
as a novel bone matrix protein, capable of mediating cell-matrix interactions, and as such may be a principal participant in organized bone formation and the regulation of remodeling.
...
PMID:Osteoblast-derived acetylcholinesterase: a novel mediator of cell-matrix interactions in bone? 1022 41